Clinical Trial Update: This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SCT510A given by intravitreal injection to ranibizumab for wet age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)
• SCT510A

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: UNKNOWN